Profile data is unavailable for this security.
About the company
Homology Medicines, Inc. is a clinical-stage genetic medicines company focused on providing treatment for rare genetic diseases. The Company’s clinical programs include HMI-103, an investigational gene editing candidate in clinical development for the treatment of patients with phenylketonuria (PKU); HMI-203, an investigational gene therapy candidate in clinical development for the treatment of patients with mucopolysaccharidosis type II (MPS II), or Hunter syndrome; and HMI-102, an investigational gene therapy candidate in clinical development for the treatment of adult patients with PKU. Its lead GTx-mAb gene therapy candidate, HMI-104, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). Its platform is designed to utilize human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs), to precisely and efficiently deliver single administration genetic medicines in vivo through a nuclease-free gene editing modality and gene therapy platform.
- Revenue in USD (TTM)3.21m
- Net income in USD-5.01m
- Incorporated2015
- Employees92.00
- LocationHomology Medicines Inc1 Patriots ParkBEDFORD 01730-2343United StatesUSA
- Phone+1 (781) 301-7277
- Fax+1 (302) 655-5049
- Websitehttps://www.homologymedicines.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Unrivaled Brands Inc | 61.91m | -210.93m | 11.29m | 170.00 | -- | -- | -- | 0.1823 | -0.3663 | -0.3508 | 0.109 | -0.0752 | 0.3954 | 4.57 | 13.75 | 185,350.30 | -134.71 | -27.36 | -314.40 | -35.79 | 31.57 | 33.96 | -340.72 | -132.54 | 0.0607 | -17.62 | -- | -- | 673.79 | 13.48 | -485.45 | -- | -- | -- |
| Trees Corp | 12.89m | -7.57m | 14.53m | 77.00 | -- | 2.00 | -- | 1.13 | -0.0838 | -0.0845 | 0.1381 | 0.0867 | 0.5095 | 7.43 | 96.11 | 167,342.30 | -29.63 | -126.64 | -34.91 | -580.81 | 39.80 | 24.38 | -58.17 | -246.71 | 1.37 | -0.371 | 0.623 | -- | -16.75 | 14.73 | 0.2624 | -- | 51.59 | -- |
| Yoshitsu Co Ltd (ADR) | 228.44m | 3.27m | 34.80m | 54.00 | 9.59 | 0.78 | 7.72 | 0.1523 | 0.1001 | 0.1001 | 7.59 | 1.23 | 1.93 | 6.60 | 5.17 | -- | 2.77 | -- | 6.53 | -- | 17.10 | -- | 1.43 | -- | 1.27 | 3.14 | 0.5812 | -- | 3.12 | -- | -40.74 | -- | -- | -- |
| Homology Medicines Inc | 3.21m | -5.01m | 54.62m | 92.00 | -- | 0.3059 | 30.69 | 17.03 | -0.0992 | -0.0992 | 0.0558 | 3.10 | 0.0146 | -- | -- | 34,869.57 | 0.2195 | -31.22 | 0.2413 | -33.71 | -- | -- | 15.06 | -818.17 | -- | -- | 0.00 | -- | -90.56 | -- | 94.77 | -- | -8.08 | -- |
| China Jo-Jo Drugstores Holdings Inc | 158.63m | -3.52m | 89.81m | 911.00 | -- | 1.01 | -- | 0.5662 | -0.9731 | -0.9731 | 39.59 | 4.36 | 1.45 | 6.96 | 9.90 | 174,127.50 | -3.22 | -8.29 | -9.51 | -23.55 | 23.98 | 22.07 | -2.22 | -5.89 | 0.7688 | -- | 0.5619 | -- | 23.48 | 15.07 | 60.69 | -- | -5.73 | -- |
| Rite Aid Corp | 24.06bn | -897.69m | 122.09m | 53.00k | -- | -- | -- | 0.0051 | -16.50 | -16.50 | 441.76 | -7.14 | 2.72 | 9.80 | 14.50 | 454,045.10 | -10.14 | -3.96 | -15.04 | -5.77 | 19.93 | 21.12 | -3.73 | -1.58 | 0.6009 | 0.3473 | 1.14 | -- | 2.18 | 1.39 | -438.10 | -- | -5.56 | -- |
| Marimed Inc | 134.01m | 13.47m | 135.22m | 592.00 | 6.29 | 2.25 | 7.16 | 1.01 | 0.063 | 0.063 | 0.426 | 0.289 | 0.9732 | 4.79 | 46.03 | 226,368.30 | 9.89 | -16.39 | 12.11 | -22.22 | 47.73 | 51.69 | 10.16 | -19.66 | 0.9313 | 31.09 | 0.2425 | -- | 10.33 | 85.70 | 86.42 | -- | -9.49 | -- |
| Tabula Rasa HealthCare Inc | 299.52m | -77.33m | 139.73m | 1.03k | -- | -- | -- | 0.4665 | -3.18 | -6.09 | 12.34 | -2.10 | 0.678 | 38.73 | 7.37 | 291,641.70 | -17.50 | -12.88 | -21.86 | -15.31 | 22.34 | 28.68 | -25.82 | -20.93 | 1.60 | -5.98 | 1.22 | -- | 15.25 | 17.54 | -48.04 | -- | 34.14 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Temasek Holdings Pte Ltd. (Investment Management)as of 31 Dec 2022 | 5.65m | 9.83% |
| The Vanguard Group, Inc.as of 31 Dec 2022 | 2.03m | 3.53% |
| Bellevue Asset Management AGas of 31 Dec 2022 | 1.62m | 2.82% |
| Citadel Advisors LLCas of 31 Dec 2022 | 1.01m | 1.76% |
| BlackRock Fund Advisorsas of 31 Dec 2022 | 917.41k | 1.60% |
| JPMorgan Asset Management (UK) Ltd.as of 31 Dec 2022 | 412.37k | 0.72% |
| Geode Capital Management LLCas of 31 Dec 2022 | 386.01k | 0.67% |
| Renaissance Technologies LLCas of 31 Dec 2022 | 333.15k | 0.58% |
| Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 31 Dec 2022 | 323.03k | 0.56% |
| Oasis Management (Hong Kong) LLCas of 31 Dec 2022 | 280.00k | 0.49% |
